1044909-61-6 Usage
Description
5-(4-chlorophenyl)-N-(2,2,3,3,4,4,5,5,6,6-decadeuteropiperidin-1-yl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide hydrochloride is a d10 labeled analogue of Rimonabant (R517800(P)). Rimonabant is a brain cannabinoid receptor (CB1) antagonist and an anti-obesity agent.
Uses
Used in Pharmaceutical Industry:
5-(4-chlorophenyl)-N-(2,2,3,3,4,4,5,5,6,6-decadeuteropiperidin-1-yl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide hydrochloride is used as a CB1 receptor antagonist for the treatment of obesity and related metabolic disorders. It helps in modulating the endocannabinoid system, which plays a crucial role in regulating appetite, energy balance, and metabolism.
Used in Research Applications:
5-(4-chlorophenyl)-N-(2,2,3,3,4,4,5,5,6,6-decadeuteropiperidin-1-yl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide hydrochloride is used as a research tool for studying the role of CB1 receptors in various physiological and pathological processes. The d10 labeled analogue allows for the investigation of receptor binding, signal transduction, and potential therapeutic targets in obesity and other related conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 1044909-61-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,4,4,9,0 and 9 respectively; the second part has 2 digits, 6 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1044909-61:
(9*1)+(8*0)+(7*4)+(6*4)+(5*9)+(4*0)+(3*9)+(2*6)+(1*1)=146
146 % 10 = 6
So 1044909-61-6 is a valid CAS Registry Number.
1044909-61-6Relevant articles and documents
Biphenyl-pyrazolecarboxamide compounds
-
Page/Page column 29, (2008/06/13)
The present invention relates to biphenyl-pyrazole compounds and in particular biphenyl-pyrazolecarboxamides. The invention further provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by antagonism or inverse agonism of the CB1 receptor, such as obesity, smoking cessation, and normalization of blood lipid composition.
